Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):848–852. doi: 10.1128/aac.38.4.848

Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones.

N Dholakia 1, K V Rolston 1, D H Ho 1, B LeBlanc 1, G P Bodey 1
PMCID: PMC284553  PMID: 8031057

Abstract

The antibacterial activity of levofloxacin was compared with those of ofloxacin and ciprofloxacin against bacterial isolates from patients with cancer. In general, levofloxacin was as active or was twofold more active than ofloxacin and was two- to fourfold less active than ciprofloxacin against most gram-negative pathogens. Against Pseudomonas aeruginosa, ciprofloxacin was the most active agent tested (MIC for 90% of isolates tested, 1.0 microgram/ml). Overall, all three agents had similar activities against gram-positive organisms and were moderately active against methicillin-susceptible Staphylococcus aureus and coagulase-negative staphylococci, Streptococcus species, and Enterococcus species.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chan C. C., Oppenheim B. A., Anderson H., Swindell R., Scarffe J. H. Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients. Antimicrob Agents Chemother. 1989 Jan;33(1):87–91. doi: 10.1128/aac.33.1.87. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Dekker A. W., Rozenberg-Arska M., Verhoef J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med. 1987 Jan;106(1):7–11. doi: 10.7326/0003-4819-106-1-7. [DOI] [PubMed] [Google Scholar]
  3. Flaherty J. P., Waitley D., Edlin B., George D., Arnow P., O'Keefe P., Weinstein R. A. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients. Am J Med. 1989 Nov 30;87(5A):278S–282S. doi: 10.1016/0002-9343(89)90080-6. [DOI] [PubMed] [Google Scholar]
  4. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fujimoto T., Mitsuhashi S. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy. 1990;36(4):268–276. doi: 10.1159/000238777. [DOI] [PubMed] [Google Scholar]
  6. Karp J. E., Merz W. G., Hendricksen C., Laughon B., Redden T., Bamberger B. J., Bartlett J. G., Saral R., Burke P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1987 Jan;106(1):1–7. doi: 10.7326/0003-4819-106-1-1. [DOI] [PubMed] [Google Scholar]
  7. Lo W. K., Rolston K. V., Rubenstein E. B., Bodey G. P. Ciprofloxacin-induced nephrotoxicity in patients with cancer. Arch Intern Med. 1993 May 24;153(10):1258–1262. [PubMed] [Google Scholar]
  8. Patel J. A., Pachucki C. T., Lentino J. R. Synergy of levofloxacin (L-ofloxacin) and oxacillin against quinolone-resistant Staphylococcus aureus, measured by the time-kill method. Antimicrob Agents Chemother. 1993 Feb;37(2):339–341. doi: 10.1128/aac.37.2.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Rolston K. V., Haron E., Cunningham C., Bodey G. P. Intravenous ciprofloxacin for infections in cancer patients. Am J Med. 1989 Nov 30;87(5A):261S–265S. doi: 10.1016/0002-9343(89)90076-4. [DOI] [PubMed] [Google Scholar]
  10. Rolston K. V., Nguyen H. T., Ho D. H., LeBlanc B., Bodey G. P. In vitro activity of Ro 23-9424, a dual-action antibacterial agent, against bacterial isolates from cancer patients compared with those of other agents. Antimicrob Agents Chemother. 1992 Apr;36(4):879–882. doi: 10.1128/aac.36.4.879. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rubenstein E. B., Rolston K., Benjamin R. S., Loewy J., Escalante C., Manzullo E., Hughes P., Moreland B., Fender A., Kennedy K. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer. 1993 Jun 1;71(11):3640–3646. doi: 10.1002/1097-0142(19930601)71:11<3640::aid-cncr2820711128>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  12. Smith G. M., Leyland M. J., Farrell I. D., Geddes A. M. A clinical, microbiological and pharmacokinetic study of ciprofloxacin plus vancomycin as initial therapy of febrile episodes in neutropenic patients. J Antimicrob Chemother. 1988 May;21(5):647–655. doi: 10.1093/jac/21.5.647. [DOI] [PubMed] [Google Scholar]
  13. Une T., Fujimoto T., Sato K., Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988 Sep;32(9):1336–1340. doi: 10.1128/aac.32.9.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Winston D. J., Ho W. G., Champlin R. E., Karp J., Bartlett J., Finley R. S., Joshi J. H., Talbot G., Levitt L., Deresinski S. Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med. 1987 Jun 26;82(6B):40–46. doi: 10.1016/0002-9343(87)90617-6. [DOI] [PubMed] [Google Scholar]
  15. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES